Cologne, Germany

Joanna Grudzinska


 

 

Average Co-Inventor Count = 10.0

ph-index = 2

Forward Citations = 9(Granted Patents)


Location History:

  • Berlin, DE (2013)
  • Cologne, DE (2016)

Company Filing History:


Years Active: 2013-2016

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Joanna Grudzinska: Pioneering Research in Monoclonal Antibodies

Introduction

Joanna Grudzinska is an accomplished inventor based in Cologne, Germany, known for her significant contributions to the field of biotechnology. With a strong background in research and development, she has been awarded two patents that showcase her innovative work in the area of monoclonal antibodies.

Latest Patents

Joanna's latest patents focus on "Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)." These patents provide isolated monoclonal antibodies that bind to the human tissue factor pathway inhibitor (TFPI). Additionally, the patents contemplate isolated nucleic acid molecules that encode these monoclonal antibodies. Furthermore, they describe pharmaceutical compositions that incorporate the anti-TFPI monoclonal antibodies and detail methods for treating deficiencies or defects in coagulation through the administration of the antibodies. Methods for producing these antibodies are also included, underscoring the practical applications of her findings.

Career Highlights

Joanna currently works at Bayer Healthcare LLC, a leading global pharmaceutical company committed to healthcare innovation. Her work there has significantly impacted therapeutic strategies involving monoclonal antibodies, offering promising solutions for coagulation disorders.

Collaborations

Throughout her career, Joanna has collaborated with notable colleagues, including Zhuozhi Wang and Junliang Pan. These partnerships highlight the collaborative nature of her research, which is essential for advancing scientific discoveries and innovations in biotechnology.

Conclusion

Joanna Grudzinska exemplifies the spirit of innovation in the field of biotechnology, particularly through her development of monoclonal antibodies targeting the tissue factor pathway inhibitor. Her patents reflect not only her expertise but also her commitment to improving therapeutic options for patients. As she continues her research at Bayer Healthcare LLC, the impact of her work will undoubtedly resonate within the scientific community and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…